151 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
August 11, 2021, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent … Act of 1995. These “forward-looking” statements include statements relating to, among other things, the consummation of the offering, the satisfaction
DRS/A
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
8 Jul 14
Draft registration statement (amended)
12:00am
determine. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Restricted Stock Agreement … . Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Stock Unit Agreement. Such conditions
8-K
EX-99.1
q0sp pcegt
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-99.1
tbb98i
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am
8-K
EX-99.1
muhn3qo
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
5f88m q8qr
30 Mar 23
Changes in Registrant's Certifying Accountant
7:02am
8-K
EX-99.1
q2l80x wj1qq
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
h3k8aksrr4h5jn6u3
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
erkqhx 35li8831
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
EX-99.1
eytgnzc ic
26 Jul 22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
4:31pm
8-K
EX-99.1
5lbn45
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
ryf0s 5x9n9ofm54rgih
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
mebgk
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
bvqr5dap
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
dbu8kl9k34 0cdopqqk
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm